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Abstract
Purpose This paper aimed to analyze the situation of the biopharmaceutical industry in Saudi Arabia to improve the situation in a
way that achieves high levels of development similar to those in Europe, the United States of America (USA), and Japan.
Methods To achieve the objective of the study, the authors surveyed 18 out of 21 Saudi pharmaceutical companies that have
received licensing for manufacturing from the Saudi Food and Drug Authority (SFDA) to diagnose the situation of manufacturing in relation to biopharmaceuticals. An interview with SFDA officials was carried out as a supplement to the survey.
Results Findings revealed a serious lack of manufacturing of biopharmaceuticals in Saudi Arabia. In addition, knowledge of
biopharmaceutical practice in upstream and downstream bioprocessing is poor. The analysis of interviews revealed some
progress in biopharmaceuticals in Saudi Arabia, namely, applications to manufacture insulin and vaccines.
Conclusion On the basis of the findings, recommendations were made to develop the situation of biopharmaceutics in Saudi Arabia.
Keywords Biopharmaceutics . Development . Saudi Arabia . Companies . SDFA

Introduction

Development in Biopharmaceutics

Biopharmaceuticals represent one of the most impressive developments in modern science [1]. In general, a pharmaceutical is a product manufactured using live organisms and has an
active ingredient, which is biological in nature. Specifically,
biopharmaceuticals are composed of living organisms
manufactured via biotechnology methods [2].
Biopharmaceuticals are defined by The European
Pharmacopeia as “target gene expression products that are
obtained through extraction and purification after gene modification in which the target gene is introduced into suitable
micro-organisms or cells via plasmids or viral vectors, thereby
promoting the expression and translation (to form corresponding proteins) of DNA” [3].

Biopharmaceuticals represent one of the most important developments in modern science [1]. The novelty in this industry
is the production of drugs via biotechnology, which is considered innovative among other related industries. The previous
study classified biopharmaceuticals into first- and secondgeneration biopharmaceuticals. The former can be classified
further into human growth hormone, G-CSF, erythropoietin,
and some human proteins manufactured using genetic recombination technology. The latter is created using genome information or via gene functional analysis [4].
First-generation biopharmaceuticals underwent great development in which the biopharmaceutical market scale in 2002
was approximately 1 trillion yen (with a 7 trillion-yen market
in relation to prescription drugs). Second-generation pharmaceuticals, such as monoclonal antibodies, are currently being
developed. Overall, the proportion of biopharmaceuticals in
relation to prescription drugs is slowly growing [4]. In 2005,
the market for biopharmaceuticals increased at a worldwide
level with yearly growth spurts of 15–33%, and their sales
exceeded $55 billion.
According to Humulin ®, recombinant human (rh) insulin
is the first biotechnology drug that has been manufactured by
Genentech, alongside Eli Lilly, and was passed by the US
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Food and Drug Administration (FDA) in 1982. Humulin ®
can be equated with the emergence of the biopharmaceutical
industry. Since its arrival, more than 100 biopharmaceuticals
have been granted permission for general use by people within
the EU and the USA [5].
In 2008, more than 120 biopharmaceuticals were present in
the global market, while more than 400 new
biopharmaceuticals were developed globally [2]. A new medicine requires more than 10 years to undergo the whole research
and development (R&D) process. This process begins with the
stage where the compound is identified and ends when it is
approved by the US FDA. On average, the amount of finances
required to develop a new medicine is approximately $2.6 billion [6]. This estimate includes the expense caused by failures,
because several compounds that are examined are not granted
FDA approval. The expense involved in such development has
risen by more than 100% over the last decade, indicating the
increasing complexity involved in the process [6].
A potential revolution in drug development strategies has
come with the new knowledge generated through the human
genome project and related biomedical research. Recombinant
protein-based therapeutics is one of the most direct applications
of this knowledge. Well-established biotechnology companies
have adopted the commercial production of these proteins [7].
Upstream and downstream processing are considered basic
steps in bioprocessing. Upstream processing is a part of biotechnology and is considered the first step in bioprocessing,
including cell isolation and cultivation. This process is followed by cell banking and culture expansion in bioreactors, and,
finally, the harvesting step. Downstream processing encompasses all process steps from cell harvest to the final purified
product and has three main steps, namely, cell disruption,
purification, and polishing [8].
Since September 2011, the FDA has approved approximately
135 biopharmaceuticals, such as recombinant antibodies, enzymes, polyethylene glycol-based products, cytokines, hormones, and other modifiers. These compounds are important
for the treatment of several potentially fatal diseases, indicating
the importance of biopharmaceuticals in the economy. The yearly return from biopharmaceuticals in the worldwide pharmaceutical industry has been steadily increasing since 2000, providing
15.19% of entire sales in the healthcare industry during 2010.
Among the top 10 medicines with the largest global revenues in
2010, half are biopharmaceuticals, and the remaining are therapeutic antibodies. The combined return reaped from these products has amounted to US$40.9 billion.

Development of Biopharmaceutics in USA
The USA is a pioneer in the biopharmaceutical industry. Its
performance exceeds that of all other nations, accounting for a
greater number of companies, higher funds in relation to
R&D, swifter regulatory permission for new products, and a

better-working public market [9]. US biopharmaceutical organizations are also global pioneers in biopharmaceutical research and commercialization [10]. Furthermore, the industry
is nearer to profitability than at any other stage in its history
[9]. The US possesses the most sophisticated biopharmaceutical industry in R&D and a wide array of products and market
scale. Most biopharmaceuticals are licensed initially in the
USA and later in other areas [3].
The biopharmaceutical field in the USA involves many
companies, which are considerably larger than those of the
European industry. The number of years since the companies
have been established slightly differs in each area, as indicated
by the enhanced market reach of US companies and their more
widely dispersed development activities and customer types.
Regarding external assistance, European companies tend to
receive governmental financial aid more often than US companies, because US firms tend to obtain such funding from
commercial entities [9]. A much higher percentage of US
firms (80.5%) cultivates early partnerships with universities
than in Europe (71.5%). This difference may be due to the US
investment in university research relating to biopharmaceutical firms, thereby ensuring that US companies have a stronger
incentive to ally with universities than their European equivalents [9].
Among the 131 pharmacy fellowship programs offered in
the USA, 58 are concentrated on developing competencies
that aid careers in the biopharmaceutical and pharmaceutical
sector. Most of the industry fellowship programs relate to
academic bodies, while others are associated with companies.
For example, Rutgers University in New Jersey, USA, has 13
business partners, yielding more than 70 pharmacy fellowships annually to ensure that students are well trained for a
pharmaceutical industrial career [11].

Development of Biopharmaceutics in China
In China’s National Twelfth Five-Year Plan, the biopharmaceutical industry was referred to as an “emerging industry of
strategic importance.” By encouraging a holistic “upgrade” of
the industry and ensuring its competitiveness, China may
achieve a large pharmaceutical industry with a robust pharmaceutical sector. This step should support the effective operation of public healthcare systems and ensure new driving
forces for economic growth [3].
China’s substantial biotechnology research bases, in conjunction with its skilled supply of workers and its relatively
low resource costs, mean that it is an attractive prospect for
biopharmaceutical firms seeking to engage in overseas
outsourcing. The Chinese government has modified policies,
enhanced investment, and improved the protection of intellectual property to encourage investment. The Chinese government facilitates this development via changes in policy,
allowing opportunities for established biopharmaceutical
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companies. Certain business commentators anticipate that
China will become the world’s third largest pharmaceutical
region, following the USA and Japan [12].
New, low-cost locations, including China and India, have a
very small contribution to worldwide biopharmaceutical research because of their low resource costs. Although biopharmaceutical growth in these nations has been swift in recent
years, its consistent size remains difficult to gauge, considering the powerful economic forces affecting agglomeration and
“clustering” in biomedical research. In terms of the effect of
worldwide development of biopharmaceutical R&D on host
country knowledge activity, foreign knowledge discovery
along biopharmaceutical companies may complement, rather
than replace, home country activities [13].

Development of Biopharmaceutics in Saudi Arabia
Biological products in the Saudi Arabia market are subject to a
marketing authorization assessment. Permission for biological
products can only be obtained when the relevant product satisfies the specifications. Such applications in relation to biological products are categorized based on the purpose of the
application. The categories are as follows: new registration,
variation, and renewal. The process begins with the validation
and concludes with either approval or rejection. The pharmaceutical industry has devised several guidelines for these processes [14].
Saudi Arabia is the most significant pharmaceutical market
in the Middle East region and has a swiftly increasing population. Its gross domestic product (GDP) is included in the top
30 worldwide. Thus, it is an encouraging market for biopharmaceutical firms. Its market was expected to rise to almost
US$5B in 2016. The healthcare system in the country is
decentralized, while decisions regarding reimbursement are
executed by specific government sectors (ministries). Recent
changes in the healthcare sector have sought to cultivate a
cost-sensitive environment. Most pharmacy departments in
specialist hospitals within the three main cities perform
pharmacoeconomic reviews. However, their effectiveness is
less than that of the clinical review.
At present, the Saudi FDA is the regulatory body dedicated
for pricing and reimbursement. Although it is a complicated
market, it is relatively large and developing. Thus, investment
may increase the profile of the country and offer attractive
opportunities for manufacturers. Considering the sizeable
population and readiness to pay for such products, Saudi
Arabia is an extremely attractive market that must be investigated by pharmaceutical companies [15].
The Ministry of Health is traditionally the main pharmaceutical regulatory body in Saudi Arabia that registers all
pharmaceutical firms operating in the country. Since the
SFDA was established in March 2003, it ultimately assumed
this role in July 2009 pursuant to Royal Decree No. M/6 of 25/

1/1428 H (13/2/2007 G). It was tasked with licensing pharmaceutical products and manufacturing facilities [16].
Saudi Arabia accounts for approximately 65% of all pharmaceutical purchases in the Gulf Cooperation Council region,
while 82% of the kingdom’s requirement is satisfied via imports,
thereby signifying a major growth opportunity for domestic
pharmaceutical organizations. Nonetheless, poor investments
in research and development due to lack of sufficiently skilled
personnel and dearth of technical knowledge and insufficient
infrastructure have led to the underdevelopment of the domestic
pharmaceutical sector. The poor or inadequate quality of pharmaceutical base materials in the country has led to the dependence of local drug manufacturers on imported materials.
Almost 90% of Saudi Arabian firms’ raw material needs are
satisfied via imports from France, Germany, Switzerland,
Belgium, and the UK. This condition increases the expense of
their activities and decreases profit margins. R&D operations are
restrained by the absence of government support and skilled
personnel, which, along with improved infrastructure, are needed to ensure the company manufactures more of its own products [17].
The potential success of the pharmaceutical sector does not
face any imminent threat, although the lack of native R&D in
this area limits the ability to manufacture new drugs locally. The
three main national organizations in the pharmaceutical industry are Saudi Pharmaceutical Industries and Medical
Appliances Corporation (SPIMACO), Tabuk Pharmaceuticals
Company, and Jamjoom Pharmacy. SPIMACO is the nation’s
most significant pharmaceutical producer and the secondranked drug company in the country. GlaxoSmithKline’s
(GSK) main facility is based in Qassim Industrial City. It manufactures more than 150 products, such as brand-name drugs
for multinational companies, in conjunction with its own forms
of prescription and OTC medication. The company’s distribution chain is operated by its subsidiary, ARAC Healthcare
Company. Its best products include antibiotics, analgesics, anti-rheumatics, vitamins, and cough/cold remedies. SPIMACO
deals with approximately 7.24% of the entire market sales in
2009 and will soon establish a SAR800 million active pharmaceutical ingredient (API) facility. To promote local production,
the government offers incentives to multinational subsidiaries
and domestic organizations. These incentives include free property leases, interest-free loans, and government subsidies [18].

Biopharmaceutical Companies’ Perception
of the Saudi Market
The major biopharmaceutical players think highly of the
Saudi market, as evidenced by the competitive existence of
these companies in the Saudi market. One of these companies
is Aurobindo, which has more than 20 manufacturing facilities
with several partnerships in India, Europe, the USA, and
Brazil. The company started investing in Saudi Arabia by
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producing medicines to treat chronic diseases, such as diabetes, heart disease, and hypertension. According to the Director
of Aurobindo Pharma, “The decision to base our company’s
regional operations in Saudi Arabia came in response to the
rising demand for our products in the ‘Arabian’”. He adds,
“Marking our entry into the Saudi market, the new factory in
the Industrial Valley will be a major turning point for our
company.” This valley hosts more than 100 companies and
can serve 250 million consumers in the Arab world and East
Africa [19].
Another prominent company is Pfizer, which is a global
pharmaceutical giant with a unique position in the market,
offering various biological products, such as vaccines, and
has a longstanding relationship with Saudi Arabia since
1960. Pfizer offers various pharmaceutical services and products covering treatment areas, including oncology, cardiovascular disease, pain, pediatric vaccinations, anti-fungal and antibacterial products, anesthesia, and critical care to patients in
Saudi Arabia. Dr. Alaa Abd El Ghany Gamal, Pfizer’s country
manager, has stated that Pfizer has a diverse portfolio and is
one of the premier biopharmaceutical companies globally and
in Saudi Arabia. He added that the Saudi government offered
an attractive proposition by providing the appropriate
supporting infrastructure for expanding their presence and
adding manufacturing facilities in the country, the alignment
of Pfizer’s goals with the country’s objectives, combined with
the impetus of Vision 2030.
He commented on the Saudi market and said that the
Kingdom has stable market dynamics of a pharmaceutical
investment with greatly improved SFDA by accelerating the
registration process, allowing the products to enter the market
faster, and facilitating the bridging process for products with
prior FDA approval in the USA or European Union for 60 or
30 working days, respectively [20].
Many European, US, and Indian companies already have
established production facilities, especially the King Abdullah
Economic Industrial Valley, which produces a full range of
products, including antibiotics, diabetic treatments, cardiovascular drugs, and anticoagulants. Opportunities abound for additional manufacturers to establish a presence in the Kingdom,
especially in vaccines, APIs, injectables, and biologics [21].
For the first time in the history of the Kingdom of Saudi
Arabia, a collaboration among biopharmaceutical industry,
academics, and research has been formed to achieve Saudi
Vision 2030. The National Industrial Clusters Development
Program (NICDP) hosted the signing of mutual memorandums of understanding to localize the vaccine manufacturing
industry in the Kingdom and improve academic research and
development in line with the latest state-of-the-art technologies and innovation in the biotechnology industry.
The Saudi Vaccine and Biomanufacturing Center hosted a
signing ceremony on March 24 in Boston, USA, in front of
HRH Crown Prince Mohammed Bin Salman. This center

aims to improve the transition into a knowledge-based economy governed by the Saudi Vision 2030. The center aims to
facilitate the translation of biological research discoveries into
commercial products, which will affect public health. The
center also adopts the latest manufacturing technologies for
the good manufacturing practice (GMP) of protein and cellbased vaccines with level 2 biosafety capabilities.
Samsung Engineering has been operating in Saudi Arabia
since 1999. It is a well-known firm that has executed 32 projects worth about 15 billion dollars worldwide and built the
largest biomanufacturing facilities in Korea. SaudiVax wants
to make Saudi Arabia self-sufficient in terms of vaccine and
biopharmaceutical manufacturing and sales, producing finished dosage formulations (sterile small injectable), active biological ingredients of biopharmaceutical products, and vaccines of importance to our territories [21].
In October 22,019, Saudi Arabian Investment Authority
signed a memorandum of understanding with Korea’s GL
Rapha Co. involving $320 million for the production of 30
biological drugs in Saudi Arabia. In addition, five other innovative products will be manufactured over the next 5 years,
covering all manufacturing stages of biological medicines,
including manufacturing raw materials [22].

Previous Studies
Studies on biopharmaceutics in Saudi Arabia are lacking. The
author aims to bridge this gap by analyzing the situation of
biopharmaceutics to reveal the strengths and weaknesses, and
the results may help in the development of this innovative
industry.
A previous study [10] analyzed 130 students enrolled in
postgraduate programs in pharmacology to explore their intentions on the pharmaceutical sector and their career paths in
this area after graduation. Students who were enrolled in their
final year of a pharmacy course at King Saud University in
Riyadh participated in the survey.
The findings of the survey revealed that more than 50% of
the students believed that an inadequate amount of information was provided regarding the facilities available to establish
pharmaceutical factories. Only 11% viewed the industrial
pharmacy as significant. Regarding the students’ projected
career paths following graduation, 8% indicated that they
would be involved in the industry. The most prominent reason
was the lack of a proper link between the industry and the
study of pharmacy in the country. Most of the students
(83.6%) claimed that they did not receive any training in the
pharmaceutical industry, while the others asserted that they
possess the knowledge and competencies required to operate
in the pharmaceutical sector following graduation. The study
indicated that pharmacy students in Saudi Arabia are not qualified to pursue a career in the pharmaceutical industry in the
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country. Several participants (29.1%) claimed that they are
unwilling to pursue a career in the pharmaceutical industry
due to the absence of a connection between universities and
the pharmaceutical industry. Exactly 52.1% stated that they
are unfamiliar with the facilities offered by the government
to establish pharmaceutical factories. The median amount of
companies of which the students were aware was as low as 2
(Riyadh Pharma and SPIMACO).
Pharmacovigilance problems in the pharmaceutical field
include the absence of drug manufacturers in Saudi Arabia.
The local pharmaceutical manufacturers in the country are
few, which represents a significant barrier to the development
of pharmaceutical industries [23].
Several studies sought to determine the percentage of pharmacists operating in the industrial field [24]. In the UK,
among 65,000 employees from various educational environments, only 2000 are both qualified and working within the
pharmaceutical industries. Notably, this number is only 3.5%
of the total industrial workforce. A survey administered by a
pharmaceutical organization in the USA illustrated that pharmacists account for 6.8% of the country’s workforce, although
they play an essential role in the company. A decrease in the
number of pharmacists studying in the industrial field was also
found. In Europe, 37,308 pharmacists operate in the industrial
field (across 28 countries) out of 603,866 industrial workers
(in 23 countries).
The Pharmacy Education in Europe study indicated that a
considerable amount (37,308) of European pharmacists (6%
of the entire workforce) operate in the industry. This figure is
similar to the global statistic of 10% provided by the
International Pharmaceutical Federation.

Aims and Objectives
This paper aimed to identify whether the companies are
manufacturing biopharmaceuticals in Saudi Arabia and to determine the causes of the lack of biopharmaceutical
manufacturing in Saudi Arabia. Moreover, it aimed to determine whether the company has biopharmaceutical
manufacturing facilities that are suitable for the manufacture
of biopharmaceuticals but does not possess suitable employees. The study sought to understand the current situation
and the views of pharmaceutical-related industries regarding
biopharmaceutical development in Saudi Arabia.
Accordingly, we employed a survey involving pharmaceutical
companies and an interview with several people having different functions and disciplines at the SFDA. Subsequently,
we analyzed the results to evaluate the biopharmaceutical industry in Saudi Arabia and its future evolution. On the basis of
such aims and objectives, the study sought to answer the following questions:

1. What is the current situation of the biopharmaceutical
industry in Saudi Arabia?
2. Is there a lack of biopharmaceutical manufacturing capability in Saudi Arabia? If yes, why?

Methods
This descriptive study utilized a combination of quantitative
and qualitative methods, appropriating the value of both
methods’ worldviews to develop a deep understanding of
the phenomenon of interest. The combination of these
methods can help capitalize on the respective strengths of each
approach [25]. The study aimed to provide a deep description
of the situation of biopharmaceutics from the perspective of
the companies in the field of biopharmaceutics and SFDA.
The combination of quantitative and qualitative methods involved corroborating findings and producing complete and
accurate data [26].

Sample of the Study
To ensure the representativeness of the sample, the author
targeted 18 of 21 Saudi pharmaceutical companies that have
received licensing for manufacturing from the SFDA to diagnose the situation of manufacturing in the field of
biopharmaceuticals. The targeted respondents were managers
or leaders responsible for the development of the company’s
products, or those who are most familiar with the field of
pharmaceuticals. Besides, three officials in the SFDA were
interviewed to obtain a clear image of the situation of
biopharmaceutics in Saudi Arabia. A total of 25 responses
were retrieved from these 18 companies. Three leaders in the
SFDA were interviewed as a supplement to the survey.

Instrumentation
The study employed a questionnaire and an interview to collect the required data. The questionnaire was designed via
SurveyMonkey program and sent to 18 pharmaceutical plants,
which were pharmaceutical facilities licensed by the SFDA in
Saudi Arabia. The questionnaire was developed by reviewing
the available content in the ISPE Baseline® Guide:
Biopharmaceutical Manufacturing Facilities (Second
Edition). ISPE applies to new facilities for the development
and manufacture of biopharmaceutical drug substances (or
APIs) that should be found in biopharmaceutical plants. The
interview that targeted SFDA principals was utilized as a supplement to the survey to obtain sufficient data and a clear
image of the situation of biopharmaceutical manufacturing
in Saudi Arabia.
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Table 1

Questionnaire design

1.
2.
3.
4.

General and plant information
Regulatory agencies (critical quality attributes and critical process parameters)
Risk management (Pharmaceutical cGMPs in the 21st century—a risk based approach)
Process closure (aseptic bioprocessing in closed aseptic systems, background information on biological risks, quality control strategies, and
knowledge of stainless-steel bioreactors)
5. Operations
6. CGMP layout approaches
7. Architectural factors
8. Mechanical matters
9. R&D departments
10. Manufacture of biopharmaceutical drugs

Questionnaire Design
To ensure the content and construct validity of the questionnaire, the author followed several adequate procedures, which
will be sketched below briefly.

Questionnaire
In the questionnaire, the author followed many procedures to
ensure the representativeness of the questionnaire for the topic
of investigation. The answers allowed for the questions were
“Yes,” “No,” and “I don’t know.” These questions highlighted
key updates to the guidance pertaining to the ISPE Baseline®
Guide. Accordingly, the questionnaire was designed to include the dimensions summarized in Table 1.

Reliability of the Questionnaire
In terms of the reliability of the questionnaire, all questions
have reasonable coefficients and were within the range of

Table 2

0.47–0.66. Cronbach’s alpha coefficient for all the survey
items was 0.7, indicating reasonable reliability.

Interview
Interviews are a popular tool for gathering information for qualitative research, because they grant opportunities for the researcher to collect meaningful information [27]. The interview targeted
three people with different functions and disciplines at the SFDA.
The questions were self-prepared to ascertain the industry views
of biopharmaceutical development. The interview was sent by email, because this method is preferred by the people at the
SFDA. The questions were clear and straightforward, and a summary of the discussion was prepared and kept for analysis. The
answers from the SFDA are important for approving the answers
of companies about manufacturing biopharmaceuticals and the
problems that companies face in relation to biopharmaceuticals
and the future of biopharmaceutical production in Saudi Arabia.
The interview included Saudi Arabia plans for biopharmaceutical
development and the potential for biopharmaceutical
manufacturing from the perspective of public health and the

Regulatory agencies that the companies follow

US Food and Drug Administration (FDA)
European Medicines Agency (EMA)
European Commission (EC), Public Health
World Health Organization (WHO)
International Conference on Harmonization (ICH)
Pharmaceutical Inspection Convention and Pharmaceutical Inspection
Co-operation Scheme (jointly referred to PICIS)
International Federation of Biosafety Association (IFBA)
Japan Pharmaceuticals and Medical Devices Agency (PDMA)
Association of Southeast Asian Nations (ASEAN)

Frequency

Percent

16
11
7
15
12
12

64.00
44.00
28.00
60.00
48.00
32

1
0
1

4.00
0.00
4
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Table 3

Regulatory issues

Questions

Yes

No

I do not know

Are critical quality attributes and critical process parameters (CPPs and CQAs) of
both current and projected future products considered in your facility’s design?
Does the company have an understanding of biopharmaceutical production,
particularly for bulk biopharmaceutical drug substance processes?
Does your company provide a closed processing facility, such as multiple closed
bioreactors, upstream operations, and downstream processing, in your site?

88.00%
22
44%
11
16%
4

4%
1
44%
11
68%
17

8%
2
12%
3
16%
4

medical economy. The questions included in the interview focused on the future of biopharmaceutical drugs in the country.

Ethical Issues
The confidentiality of the information was ensured through
anonymity and its sole use for the purpose of this project.
The survey envelopes contained the first letter of the confidentiality of the participant’s responses, indicating that their
responses would remain strictly anonymous and confidential.
The participants’ responses were reported and analyzed in a
manner that they cannot be linked or traced to any individual.

Results
This section presents the results of the survey and interview.
The results were structured based on the data retrieved by the
instruments. The results of the questionnaire were structured
in accordance with the main sections. The interview responses
were analyzed qualitatively.

Questionnaire
The results of the questionnaire were structured based on the
main elements of the questionnaire (regulatory agencies, risk
management, process closure, operations, CGMP layout approaches, architecture, mechanical, R&D, and manufacture).
Table 4

Regulatory Issues
This section consists of four questions. The first question concerns the regulatory agencies with which the company complies.
The companies’ responses revealed that they complied with the
following agencies: US FDA, European Medicines, European
Commission, World Health Organization, International
Conference on Harmonization, Pharmaceutical Inspection
Convention, International Federation Biosafety Association,
Japan Pharmaceutical and Medical Diverse Agency, and
Association of Southeast Asian Nations (Table 2).
The second question revealed that 88% of the facility’s design
of the companies consider critical quality attributes and process
parameters (CPPs and CQAs) of both current and projected future products, and the other responses were distributed between
No (4%) and I don’t know (8%). The responses to the third
question revealed that 44% agreed, 44% disagreed, and 12%
did not know whether their companies understand biopharmaceutical production (bulk biopharmaceutical drug substance processes). The responses to the fourth question revealed that 16%
agreed and 68% disagreed that the companies provide a closed
processing facility, such as multiple closed bioreactors, upstream
operations, and downstream processing, whereas 16% were not
aware of any (Table 3).
Risk Management
This section consists of four questions that aim to explore how
the targeted companies manage risks. The responses to the first

Management risk

Question

Yes

No

Do not know

1. Does your company provide a method for evaluating the risks of
cross-contamination and contamination from the environment during
the manufacturing of bulk drug substances, specifically during bioprocessing?
2. Does your company have knowledge of the use of risk management in the
biopharmaceutical industry?
3. Are the risk assessments in your company incorporated into corrective
action and preventative action (CAPA) programs?
4. Do you have methods and approaches used for assessing risks in
biopharmaceutical manufacturing in your company?

64%
16

28%
7

8%
2

52%
13
92%
23
40%
10

32%
8
0
0
56%
14

16%
4
8%
2
4%
1
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Table 5

Process closure

Questions

Yes

No

I do not know

Does your company have information about the importance of performing
aseptic bioprocessing in a closed aseptic system?
Does your company have background information regarding the biological
risks to a biopharmaceutical process and the products of particulates and
bioburden contamination (such as bacteria, yeasts, or mold contamination)
in the environment?
Does your company provide quality control strategies and appropriate storage
conditions to mitigate and monitor the risk of contamination from raw materials?
Does your company have an effective cleaning and sanitation program?

56%
14
68%
17

28%
7
24%
6

%16
4
8%
2

96%
24
92%
23
68%
17
72
18

0
1
4%
1
20%
5
20%
5

4%
1
4%
1
12%
3
8%
2

32%
8

60%
15

8%
2

Does your company provide different approaches and layers of protection to mitigate
the risk of contamination from the environment to a bioprocess unit operation?
Does your company use risk assessments to demonstrate that a process has been
successfully isolated from the surrounding environment and that the environment
no longer represents a critical aspect of this process?
Does your company have knowledge of stainless-steel bioreactors used in a cell
culture operation in the biopharmaceutical field?

question revealed that 64%, 28%, and 8% agreed, disagreed,
and did not know that their companies provide a method for
evaluating the risks of cross-contamination and contamination
from the environment during the manufacturing of bulk drug
substances, respectively. The second question revealed that
52%, 32%, and 16% agreed, disagreed, and did not know that
their company has the knowledge about the use of risk management in the biopharmaceutical industry. The responses to
the third question revealed that 92% of the companies incorporated risk assessment into corrective and preventative action
programs. The fourth question’s responses revealed that 40%,
56%, and 4% agreed, disagreed, and did not know that their
companies employ methods and approaches for assessing risks
in biopharmaceutical manufacturing (Table 4).

risks, respectively. Most of the participants (96%) agreed that
their companies provided quality control strategies and appropriate storage conditions to mitigate and monitor the risk of
contamination from raw materials. Similarly, 92% agreed that
their companies have an effective cleaning and sanitization
program. Exactly 86%, 20%, and 12% agreed, disagreed,
and did not know that their companies provide different appro ache s and layer s of pro tection , resp ective ly.
Approximately 72%, 20%, and 8% agreed, disagreed, and
did not know that their companies use risk assessment, respectively. The last section revealed that 32%, 60%, and 8%
agreed, disagreed, and did not know that their companies have
knowledge about stainless-steel bioreactors (Table 5).

Process Closure

Operations

The process closure consists of seven items. The responses to
the first question revealed that 68%, 28%, and 16% agreed,
disagreed, and did not know that their companies have information about the importance of performing aseptic
bioprocessing, respectively. For the companies’ background
of biological risks, 68%, 24%, and 8% agreed, disagreed, and
did not know about their companies’ background of biological

Regarding operations, 48% and 52% agreed and disagreed
that their companies consider the operational aspects of a biopharmaceutical facility and the effects of facility and equipment design decisions on manufacturing operations, respectively. Exactly 28%, 60%, and 12% agreed, disagreed, and did
know that they dealt with a single-use system in their site,
respectively (Table 6).

Table 6

Operations

Questions

Yes

No

Do not know

Does your company consider the operational aspects of a biopharmaceutical
facility and the effects of facility and equipment design decisions on
manufacturing operations?
Have you ever dealt with a single-use system in your site?

48%
12

52%
13

0%
0

28
7

60
15

12%
3
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CGMP layout approaches

Questions

Yes

No

Do not know

Is the facility layout in your manufacturing plant focused on
protecting the product?
Is your company aware that production scale and process technology
improvements can significantly affect facility layout?
Does your company prevent product contamination by segregating
sources of product contamination from the product?
Does your company have environmental protection of an exposed
product, such as a classified clean room environment?
Does your company provide facility and process flows that are designated
paths of travel for personnel, materials, product, equipment cleaning, and solid waste?

88%
22
84%
21
88%
22
92%
23
96%
24

8%
2
0
0
8%
2
4%
1
0
0

4%
1
16%
4
4%
1
4%
1
4%
1

CGMP Layout Approaches
This section includes five questions. The responses to the first
question revealed that 88%, 8%, and 4% agreed, disagreed,
and did not know that the facility layout in their manufacturing
plant focused on protecting the product, respectively. Exactly
84% and 16% agreed and disagreed that their companies were
aware that production scale and process technology improvements can significantly affect facility layout, respectively. The
responses to the third question revealed that 88%, 8% and 4%
agreed, disagreed, and did not know that their companies prevent product contamination by segregating sources of product
contamination from the product, respectively. Most of the respondents (92% and 96%) agreed with the last two questions
(Table 7).
Architecture
Regarding architecture, 48%, 40%, and 12% agreed,
disagreed, and did not know that the facility design of
biopharmaceuticals and vaccines have features of concern
for their company, respectively (Table 8).
Mechanical Matters
This section includes three questions. Exactly 44%, 32%, and
24% agreed, disagreed, and did not know that their companies
evaluate each step in the manufacture of a biopharmaceutical
drug substance for risk factors, respectively. Exactly 84%,
12%, and 4% agreed, disagreed, and did not know that their
companies provide an HVAC system that enhances or

Table 8

provides appropriate environmental parameters. Finally,
60%, 24%, and 16% agreed, disagreed, and did not know that
their companies follow the classification of critical environments in biotechnology and vaccine facilities on the basis of
airborne particulate concentration, as outlined in ISO, respectively (Table 9).
Table 10 shows the classification that the companies follow
in compliance with environmental control requirements.

R&D
Regarding R&D, 80% and 20% agreed that they perform
R&D in their companies, respectively. Approximately 20%,
60%, and 20% agreed, disagreed, and did not know that their
companies are interested in biopharmaceutical research, respectively. Exactly 12%, 68%, and 12% agreed, disagreed,
and did not know that they have domestic researchers for
recruitment in biopharmaceutical research, respectively
(Table 11).
Manufacture
All participants disagreed that their companies manufactured
biopharmaceutical drugs. Exactly 28%, 36%, and 36%
agreed, disagreed, and did not know that they seek to manufacture biopharmaceutical drugs, respectively. About 76% and
24% disagreed and did not know that they have biopharmaceutical drugs un der developmen t, re sp ectively.
Approximately 10.53%, 78.95%, and 10.53% agreed,
disagreed, and did not agree with the availability of a biological safety program in their work area, respectively. A total of

Architecture

Questions

Yes

No

I do not know

Do you believe that the facility design of biopharmaceuticals and
vaccines have features of concern for your company?

48%
12

40%
10

12%
3
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Table 9

Mechanical matters

Questions

Yes

No

I do not know

If the company manufactures biopharmaceutical drugs, does it evaluate
each step in the manufacture of a biopharmaceutical drug substance
for risk factors?
Does your company provide an HVAC system that enhances or provides
appropriate environmental parameters?
Does your company follow the classification of critical environments in
biotechnology and vaccine facilities on the basis of airborne particulate
concentration, as outlined in ISO?

44%

32%

24%

84%

12%

4%

60%

24%

16%

88% and 12% disagreed and did not know that they have
biosafety containment for recombinant DNA molecules.
Approximately 33.33%, 16.67%, and 50% agreed, disagreed,
and did not know that biosafety containment is a barrier to the
manufacture of biopharmaceutical drugs, respectively.
Exactly 24%, 28%, and 45% agreed, disagreed, and did not
know that they will develop biopharmaceuticals in the future,
respectively. Moreover, 44%, 16%, and 40% agreed,
disagreed, and did not know that clinical trials are the main
problem for biopharmaceutical manufacturers, respectively
(Table 12).
The main problems that the companies face in developing
innovation dugs are listed in Table 13.

Interview
Interviews were conducted as a supplement to the survey. The
interviews targeted three officials in the SFDA. The interview
was structured in the form of open questions (Table 14).

Discussion
Results revealed a severe lack of biopharmaceutical production in Saudi Arabia, as indicated by the results of the questionnaire for companies. About 100% of companies do not
manufacture biopharmaceuticals, as supported by the SFDA
officials’ responses in the interview. According to the SFDA,
only one company is engaged in secondary packaging of some
Table 10

vaccines. GSK’s main facility is based in Qassim Industrial
City. It manufactures more than 150 products, such as brandname drugs for multinational companies, in conjunction with
its own forms of prescription and OTC medication [17]. The
company seeks to produce more than four biopharmaceutical
drugs, including HIV drugs, over the next 5 years.
Three people of different functions and disciplines at the
SFDA stated that two companies have applied for biopharmaceutical manufacturing, but operations have not begun. These
companies aim to manufacture vaccines and insulin. The
SFDA interviewees did not clarify the types of vaccines that
the companies seek to manufacture.
The findings revealed the willingness of companies to manufacture biopharmaceuticals. As mentioned in the literature review, Saudi Arabia is the most significant pharmaceutical market
in the Middle East region and has a rapidly increasing economy.
Its GDP is included in the top 30 worldwide. Thus, it is an
encouraging market for biopharmaceutical firms [15].
However, biopharmaceutical production in the country is
lacking.
Notably, the lack of reliability affected a portion of the
answers provided for this research. Inaccurate responses (“I
don’t know”) meant that the intended meaning was unclear on
certain occasions. This scenario may be due to the shortcomings in the respondent’s knowledge of biopharmaceutical
manufacturing. Conversely, it possibly resulted from the misinterpretation of the nature of the question asked.
Considering the experience of or the perception of the risk
of biopharmaceutical manufacturing-related problems in

Classification that the companies follow

What is the classification that your company follows regarding environmental
control requirements? (Please tick those which apply.)

Classification

Percent

ISO 14644-3

76.19
16
66.67
14
14.29
3

EU and PIC/S
ISPE grade
PIC/S Grad

9.52
2
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R&D

Questions

Yes

No

I do not know

Do you have an R&D department in your company?

80%
20
20%
5
12%
3

20%
5
60%
15
68%
17

0%

If so, is the R&D in your company interested in biopharmaceutical research?
Do you have domestic researchers for recruitment in biopharmaceutical research?

clinical trials, the SFDA interviewees asserted, “No, there are
requirements (GMP certificate and certificate of analysis) to
minimize biopharmaceutical manufacturing-related problems.” Moreover, they claimed that the reason underlying
the lack of biological medicine manufacture in Saudi Arabia
was the difficulty of clinical trials and financial problems.
About 76% of the problems that many companies face in
developing innovative biopharmaceutical drugs were attributed to design facilities. Financial problems and research problems were the second most common problems related to
manufacturing biopharmaceuticals in Saudi Arabia, accounting for 68% and 60%, respectively. The ISPE book was set as
the reference point for the preparation of the questionnaire in
terms of the responses. The most common problem that many
companies face in developing innovative drugs (biologicals/
biotech) is the design of the facility. The availability of facilities for the manufacture of biopharmaceuticals is required for
the industrialization of biopharmaceuticals in Saudi Arabia.
Poor investment in R&D is due to the lack of sufficiently
skilled personnel, resulting in a dearth of technical knowledge
and insufficient infrastructure. Moreover, poor production of
pharmaceutical-based materials in the country has led to the
dependence of local drug manufacturers on imported
Table 12

20%
5
12%
3

materials. Almost 90% of Saudi Arabian firms’ raw material
needs are satisfied via imports from France, Germany,
Switzerland, Belgium, and the UK [16].
In general, the companies have the essential requirements
for manufacturing pharmaceuticals but not in regard to the
specific requirements of biopharmaceuticals. For example,
only 16% of companies provide a closed processing facility,
such as multiple closed bioreactors, upstream operations, and
downstream processing. Closed processing dissociates the
process from the facility and isolates the process from neighboring activities effectively to provide safety for products.
Some answers are inconsistent. For instance, 16% answered
that the company provides closed processing facilities, such as
multiple closed bioreactors, upstream operations, and downstream processing, whereas no company manufactures
biopharmaceuticals. In addition, regarding the availability of
a biological safety program in the company working area, for
the company with biopharmaceutical drugs that are under development, approximately 79% answered No, and this answer
contradicts the answers in part 2 of the survey concerning risk
management. This inconsistency is related to indifference or
misunderstanding due to the language barrier in relation to
some respondents.

Manufacture

Questions

Yes

No

I do not know

Is the company manufacturing biopharmaceutical drugs?

0%
0
28%
7
0%
0
10.53%
2
0%
0
33.33%
8
24%
6
44%
11

100%
25
36%
9
76%
19
78.95%
15
88%
22
16.67%
4
28%
7
16%
4

0%
0
36%
9
24%
6
10.53%
2
12%
3
50%
12
48%
12
40%
10

Are you seeking to manufacture biopharmaceutical drugs?
Do you have biopharmaceutical drugs under development?
If so, do you have a biological safety program in your working area?
Do you have biosafety containment for recombinant DNA molecules?
If not, do you think biosafety containment is a barrier to the
manufacture of biopharmaceutical drugs?
Do you plan to develop biopharmaceuticals in the future?
Do you believe that clinical trials are the main problem for
biopharmaceutical manufacturers?
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Table 13

Classification of problems

Questions

Problems

Frequency Percent

What kinds of financial
or other problems
may companies face
in the development of
innovative drugs
(biologicals/biotech)?

Financial problems
Design facility problems
Equipment problems
Research problems
Scientific problems
Clinical trial problems
Reasons for your
answers above, and if
you have other
problems (please
specify):

17
19
12
15
9
14
1

68.00
76.00
48.00
60.00
36.00
56.00
4.00

About 60% of companies are not interested in biopharmaceutical research, and 68% do not have domestic researchers
for recruitment in biopharmaceuticals. Although the lack of
native R&D in relation to the area is a serious hindrance to the
ability to manufacture new drugs locally, the potential success
of the pharmaceutical sector faces no imminent threats [17].
By contrast, the USA possesses the most sophisticated biopharmaceutical industry in terms of R&D and a wide array of
products and market scale. Most biopharmaceuticals are licensed initially in the USA and later in other areas [3].
In China, the development of the biopharmaceutical industry is achieved via an approach that extends across the

Table 14

whole nation, involving R&D policy, which is guided by
the government and energetic participation facilitated by
research organizations and performed mainly by manufacturers [3]. Progress in the R&D of the USA and China
indicates the importance of research and development in
the biopharmaceutical field, thereby supporting that research will enhance the biopharmaceutical industry of
Saudi Arabia.
For the regulatory procedure (marketing authorization procedure) that biopharmaceutical companies should follow, the
SFDA interviewees referred to the latest version 5.0 of the
guidance titled “Regulatory framework for drug approvals.”
The biological products that are intended for the Saudi Arabia
market are subject to a marketing authorization assessment.
Several guidelines have been devised in relation to biological
products, and these guidelines are categorized based on the
purpose of their application, including new registration, variation, and renewal [13].

Conclusion
This research aimed to evaluate the situation of the biopharmaceutical industry in Saudi Arabia in terms of the revolution
in biopharmaceuticals worldwide. Accordingly, the research
methodology involved a combination of quantitative and

Interview

No. Questions

Answers

1

Two companies are manufacturing biopharmaceutical drugs,
but they have not commenced yet.
Financial problems
Difficulty of clinical trials

2

3

4.

How many companies are manufacturing
biopharmaceutical drugs?
If there is no manufacture of biopharmaceutical
drugs, what causes the lack of biological
medicine manufacture in Saudi Arabia?
In general, what kinds of biopharmaceutical
drugs is the country most interested in?

Do you have biopharmaceutical drugs under development?
What kind of a regulatory procedure (marketing authorization
procedure)
should biopharmaceutical companies follow (i.e., at which
points should the regulatory authorities treat
biopharmaceuticals differently)?
From which of these countries has Saudi Arabia imported
biopharmaceutical drugs or considered doing so?
Have you experienced, or do you think that a risk of
biopharmaceutical manufacturing-related problems
may occur in clinical trials?
Have you experienced, or do you think that problems
may arise in the clinical studies of biopharmaceuticals?

The SFDA regulates all kinds and subtypes of biological
products, including vaccines, blood and blood components,
allergens, somatic cells, gene therapy, tissues and
recombinant therapeutic proteins, and biosimilar medicines.
No companies have been able to register biopharmaceutical
drugs until now.
Please refer to the latest version 5.0 of the guidance
titled “Regulatory framework for drug approvals”
accessed at < http://old.sfda.gov.sa/en/drug/drug_reg/Pages/drug_reg.
aspx
The USA, Canada, the UK, Japan, and Korea
No. Some requirements (GMP certificate and certificate of analysis)
are set to minimize biopharmaceutical manufacturing-related
problems.
Any clinical trial involves potential risks, and the approval
depends on the benefit-risk assessment. No specific
problems exist for clinical studies of biopharmaceuticals.
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qualitative methods to develop a deep understanding of the
phenomenon of interest.
Findings revealed a serious lack of biopharmaceutical manufacture in Saudi Arabia. Facility design is a major challenge for
companies, followed by financial and research problems. Most
companies aim toward manufacturing biopharmaceuticals in the
next few years. The future of the biopharmaceutical field in the
country is promising, as revealed by the interview with the
SFDA personnel, who clarified that two companies have applied
to the SFDA to manufacture insulin and vaccines but operations
have not begun. This initiative is promising, although the progress is behind the revolution of biopharmaceuticals worldwide.

2.
3.

4.
5.
6.
7.

8.

Recommendations
On the basis of the findings, the study recommended that Saudi
Arabia should engage in workshops similar to those provided by
the National Institute for Bioprocessing Research & Training
(NIBRT) in Ireland. This world-renowned body offers training
in relation to the bioprocessing industry, thereby aiding the
bioprocessing industry by facilitating a particular learning process within a rail that reflects the latest industrial bioprocessing
facilities. The NIBRT also offers important research in significant
areas of bioprocessing in partnership with the industry (NIBRT,
2016). This step will provide Saudi Arabia’s biopharmaceutical
industry employees with the ability to improve and develop the
biopharmaceutical industry in Saudi Arabia.
Foreign investment should be encouraged in Saudi Arabia,
especially investment from companies with experience in
biopharmaceuticals. Accordingly, these experiences will be
shared among the pharmaceuticals sector, because of the
country’s interest in the pharmaceutical industry. Thus,
Saudi Arabia is a good location for the companies to explore.
Regarding the survey, most of the participants were not
from Saudi Arabia. Few Saudi Arabians are involved in the
field of industrial pharmacy. From the author’s perspective
and on the basis of the literature review, the university curriculum features a significantly poor design in relation to general
pharmaceutical industrial practices, especially in the biopharmaceutical industry, which has been clarified and discussed in
this research. The disconnect between colleges and the pharmaceutical industry is the main reason for the gap between
them. The pharmaceutical industry lacks biopharmaceutical
manufacture and pharmacy practice, and this area needs further investigation.
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